Clinical Trials
3 trialsNCT03445533 2022-11-08
A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma
Idera Pharmaceuticals, Inc.
Phase 3 Terminated
NCT02644967 2022-08-03
ILLUMINATE-204
Idera Pharmaceuticals, Inc.
Phase 2 Completed
NCT03052205 2020-02-11
ILLUMINATE-101
Idera Pharmaceuticals, Inc.
Phase 1 Completed